The study published on May 28, 2024, in the Journal of Dietary Supplements revealed significant D-mannose limitations compared to Ellura on anti-adhesion activity against UTI-causing bacteria. ATLANTA, July 22, 2024 /PRNewswire/ -- Solv Wellness®, a women's health company with a focus on pelvic health, is announcing groundbreaking research showing that Ellura®, a 36mg proanthocyanidin (PAC) standardized cranberry juice-based dietary supplement, provides consumers with more broad-spectrum benefit against UTI-causing bacteria than D-mannose..

2024年5月28日发表在《膳食补充剂杂志》上的这项研究显示，与Ellura相比，D-甘露糖对引起UTI的细菌的抗粘附活性有明显的限制。亚特兰大，2024年7月22日/PRNewswire/--Solv Wellness®，一家专注于骨盆健康的女性健康公司，宣布了开创性的研究，表明Ellura®是一种36mg原花青素（PAC）标准化的蔓越莓汁基膳食补充剂，与D-甘露糖相比，为消费者提供了更广泛的抗UTI细菌的益处。。

Continue Reading

The bioavailable PAC in Ellura was shown to bind to both types of E. coli bacteria, P-type and Type 1, and exhibited favorable AAA, giving participants broader benefit against UTI-causing bacteria when compared to D-mannose.

Ellura中的生物可利用PAC显示与P型和1型两种类型的大肠杆菌细菌结合，并表现出良好的AAA，与D-甘露糖相比，参与者对引起UTI的细菌有更广泛的益处。

Urinary tract infections (UTI) are caused by bacteria adhering to the walls of the urinary tract, so preventing this step allows the bacteria to flush harmlessly out of the body in the urine stream. In the Journal of Dietary Supplements study, participants took either Ellura or D-mannose over 1-week periods and collected their urines at various time points.

尿路感染（UTI）是由粘附在尿路壁上的细菌引起的，因此防止这一步骤可以使细菌无害地从尿流中冲出体外。在《膳食补充剂杂志》的研究中，参与者在1周内服用Ellura或D-甘露糖，并在不同时间点收集尿液。

Urines were then tested for bacterial anti-adhesion activity (AAA) against P-type and Type 1 Escherichia coli (E. coli), the two most common UTI-causing bacteria..

然后测试尿液对P型和1型大肠杆菌（大肠杆菌）的细菌抗粘附活性（AAA），这是两种最常见的引起UTI的细菌。。

Results demonstrated that Ellura effectively and consistently prevented adhesion of both types of E. coli, but D-mannose's AAA was inconsistent and notably limited, particularly against P-type E. coli which are implicated in causing potentially serious kidney infections.

结果表明，Ellura有效且始终如一地阻止了两种类型的大肠杆菌的粘附，但D-甘露糖的AAA不一致且显着受限，特别是针对P型大肠杆菌，其涉及引起潜在的严重肾脏感染。

While both cranberry supplements and D-mannose are commonly used to help prevent UTIs, it is critical that healthcare providers and UTI sufferers are aware of which ingredients are scientifically validated and proven to support optimal urinary tract health.Key Findings from the Study

虽然蔓越莓补充剂和D-甘露糖都常用于预防UTI，但至关重要的是，医疗保健提供者和UTI患者要知道哪些成分经过科学验证并证明可以支持最佳的尿路健康。研究的主要发现

D-mannose did not prevent the adhesion of P-type E. coli in urine, a bacteria that can cause kidney infections.

D-甘露糖不能阻止P型大肠杆菌在尿液中的粘附，这种细菌可以引起肾脏感染。

After taking D-mannose, there was some AAA against Type 1 E. coli in urine that can lead to bladder infections, but it was not consistent. This activity could not be directly attributed to D-mannose, but to an adhesion inhibitor the body naturally produces called Tamm-Horsfall protein. These results cast doubt on the benefits of taking D-mannose for the maintenance of urinary tract health..

服用D-甘露糖后，尿液中存在一些针对1型大肠杆菌的AAA，可导致膀胱感染，但并不一致。这种活性不能直接归因于D-甘露糖，而是归因于人体自然产生的一种称为Tamm-Horsfall蛋白的粘附抑制剂。这些结果使人怀疑服用D-甘露糖对维持尿路健康的益处。。

Ellura significantly prevented adhesion of both P-type and Type 1 bacteria in a consistent manner over the course of the study.

在研究过程中，Ellura以一致的方式显着阻止了P型和1型细菌的粘附。

The effectiveness of Ellura was mainly attributed to its active ingredient, 36mg of soluble (bioavailable) juice-based PAC, the cranberry component that has demonstrated potent bacterial AAA in many previous studies.

Ellura的有效性主要归因于其活性成分36mg可溶性（生物可利用）果汁基PAC，这种蔓越莓成分在许多先前的研究中已经证明了有效的细菌AAA。

This Journal of Dietary Supplements study comes on the heels of a large-scale clinical trial of nearly 600 women published in April 2024 in the Journal of the American Medical Association (JAMA) Internal Medicine that found no reduction in recurrent UTIs when D-mannose was taken daily over 6 months.

《膳食补充剂杂志》的这项研究紧随其后，2024年4月在《美国医学会（JAMA）内科杂志》上发表了一项针对近600名女性的大规模临床试验，该试验发现，在6个月内每天服用D-甘露糖时，复发性泌尿道感染没有减少。

The authors concluded that D-mannose should not be recommended for UTI prevention.Results of the new study support the JAMA clinical findings, providing further insights into the lack of effectiveness of D-mannose and positioning Ellura as the clear alternative, providing broad-spectrum, reliable benefits for maintaining urinary tract health.

作者得出结论，不应推荐D-甘露糖用于预防UTI。这项新研究的结果支持了JAMA的临床发现，为D-甘露糖缺乏有效性提供了进一步的见解，并将Ellura定位为明确的替代品，为维持尿路健康提供了广谱，可靠的益处。

Read the full press release of the JAMA study here.Moreover, the results address the concerns highlighted in the 2022 Cochrane Database of Systematic Reviews where it is stated, 'There is currently little to no evidence to support or refute the use of D-mannose to prevent or treat UTIs in all populations.' By demonstrating the limited efficacy of D-mannose and establishing Ellura, with its standardized 36mg level of highly active cranberry PAC, as a more effective choice for preventing adhesion of the bacteria that cause UTIs, healthcare providers and recurrent UTI sufferers have more valuable insights into evidence-based UTI management strategies. Understanding Effective Cranberry SupplementsCurrent study researchers make a significant point that should be heavily considered by consumers when assessing the bioactivity of different cranberry supplements.

阅读JAMA研究的完整新闻稿。此外，研究结果解决了2022年Cochrane系统评价数据库中强调的问题，其中指出，“目前几乎没有证据支持或驳斥使用D-甘露糖预防或治疗所有人群的UTI。”通过证明D-甘露糖的有限功效并建立Ellura，其标准化的36mg水平的高活性蔓越莓PAC，作为预防引起UTI的细菌粘附的更有效选择，医疗保健提供者和复发性UTI患者对循证UTI管理策略有更有价值的见解。了解有效的蔓越莓补充剂当前的研究人员提出了一个重要的观点，消费者在评估不同蔓越莓补充剂的生物活性时应该充分考虑这一点。

They explain not every cranberry supplement provides sufficient AAA, which is why it's critical for consumers to take a urinary tract health supplement that contains 100% soluble PAC extracted from only pure cranberry juice, like Ellura.Amy Howell, PhD, Philip E. Marucci Center for Blue.

他们解释说，并不是每种蔓越莓补充剂都能提供足够的AAA，这就是为什么消费者服用含有100%可溶性PAC的泌尿道健康补充剂至关重要，该补充剂仅从纯蔓越莓汁（如Ellura）中提取。Amy Howell博士，Philip E.Marucci蓝色中心。